Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phentermine/topiramate - VIVUS

Next Previous
Drug Profile

Phentermine/topiramate - VIVUS

Alternative Names: Phentermine and topiramate extended-release capsules - VIVUS; Phentermine/CR topiramate - VIVUS; Qnexa; Qsiva; QSYMIA; Qsymia; Topiramate/phentermine; VI-0521

Latest Information Update: 18 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VIVUS
  • Developer Alvogen; VIVUS
  • Class Amphetamines; Anorectics; Antihyperglycaemics; Dioxolanes; Hepatoprotectants; Hexoses; Ketoses; Sleep disorder therapies; Small molecules; Sulfonic acids
  • Mechanism of Action Adrenergic receptor agonists; AMPA receptor antagonists; Carbonic anhydrase inhibitors; Central nervous system stimulants; GABA A receptor agonists; Glutamate agonists; Kainic acid receptor antagonists; Neurotransmitter stimulants; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Obesity
  • Phase II Sleep apnoea syndrome; Type 2 diabetes mellitus
  • No development reported Non-alcoholic steatohepatitis

Most Recent Events

  • 10 Mar 2025 Launched for Obesity (In adults, In children, In the elderly, In adolescents) in United Arab Emirates (PO)
  • 23 Oct 2024 Registered for Obesity in United Arab Emirates (PO)
  • 07 Oct 2024 Launched for Obesity in Poland, Norway, Iceland, Finland, Denmark, Denmark (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top